Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (2225)
All Articles published online
|
Jan 14, 2007 (publication date) through Dec 24, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Boeck S, Hinke A, Wilkowski R, Heinemann V. Importance of performance status for treatment outcome in advanced pancreatic cancer. World J Gastroenterol 2007; 13(2): 224-227 [PMID: 17226900 DOI: 10.3748/wjg.v13.i2.224] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v13/i2/224.htm |
| Number | Citing Articles |
| 1 |
C Mel Wilcox, Hwasoon Kim, Toni Seay, Shyam Varadarajulu. Choice of plastic or metal stent for patients with jaundice with pancreaticobiliary malignancy using simple clinical tools: a prospective evaluation. BMJ Open Gastroenterology 2015; 2(1): e000014 doi: 10.1136/bmjgast-2014-000014
|
| 2 |
Emine Canyilmaz, Lasif Serdar, Gonca Hanedan Uslu, Gulsen Soydemir, Zumrut Bahat, Adnan Yoney. Evaluation of Prognostic Factors and Survival Results in Pancreatic Carcinomas in Turkey. Asian Pacific Journal of Cancer Prevention 2013; 14(11): 6573 doi: 10.7314/APJCP.2013.14.11.6573
|
| 3 |
Giuseppe Colloca. Performance status as prognostic factor in phase III trials of first‐line chemotherapy of unresectable or metastatic pancreatic cancer: A trial‐level meta‐analysis. Asia-Pacific Journal of Clinical Oncology 2022; 18(3): 232 doi: 10.1111/ajco.13598
|
| 4 |
Jun Tian, Zhen-chun Chen, Li-Fang Hang. Effects of nutritional and psychological status of the patients with advanced stomach cancer on physical performance status. Supportive Care in Cancer 2009; 17(10): 1263 doi: 10.1007/s00520-009-0579-5
|
| 5 |
S. Boeck, T. Hoehler, G. Seipelt, R. Mahlberg, A. Wein, A. Hochhaus, H.-P. Boeck, B. Schmid, E. Kettner, M. Stauch, F. Lordick, Y. Ko, M. Geissler, K. Schoppmeyer, G. Kojouharoff, A. Golf, S. Neugebauer, V. Heinemann. Capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (mGemOx): final results of a multicenter randomized phase II trial in advanced pancreatic cancer. Annals of Oncology 2008; 19(2): 340 doi: 10.1093/annonc/mdm467
|
| 6 |
Jhe-Cyuan Guo, Shih-Hung Yang. Sequential gemcitabine and platinum versus first-line combination of gemcitabine and platinum for advanced pancreatic cancer treatment: a retrospective study. International Journal of Clinical Oncology 2014; 19(4): 634 doi: 10.1007/s10147-013-0622-x
|
| 7 |
Xiu-Wei Zhang, Yu-Xiang Ma, Yang Sun, Yu-Bo Cao, Qin Li, Chong-An Xu. Gemcitabine in Combination with a Second Cytotoxic Agent in the First-Line Treatment of Locally Advanced or Metastatic Pancreatic Cancer: a Systematic Review and Meta-Analysis. Targeted Oncology 2017; 12(3): 309 doi: 10.1007/s11523-017-0486-5
|
| 8 |
Volker Heinemann, Michael Haas, Stefan Boeck. Systemic treatment of advanced pancreatic cancer. Cancer Treatment Reviews 2012; 38(7): 843 doi: 10.1016/j.ctrv.2011.12.004
|
| 9 |
Ana Custodio, Javier Puente, Javier Sastre, Eduardo Díaz-Rubio. Second-line therapy for advanced pancreatic cancer: A review of the literature and future directions. Cancer Treatment Reviews 2009; 35(8): 676 doi: 10.1016/j.ctrv.2009.08.012
|
| 10 |
M Cantore, R Girelli, A Mambrini, I Frigerio, G Boz, R Salvia, A Giardino, M Orlandi, A Auriemma, C Bassi. Combined modality treatment for patients with locally advanced pancreatic adenocarcinoma. British Journal of Surgery 2012; 99(8): 1083 doi: 10.1002/bjs.8789
|
| 11 |
N. Starling, E.A. Hawkes, I. Chau, D. Watkins, J. Thomas, J. Webb, G. Brown, K. Thomas, Y. Barbachano, J. Oates, D. Cunningham. A dose escalation study of gemcitabine plus oxaliplatin in combination with imatinib for gemcitabine-refractory advanced pancreatic adenocarcinoma. Annals of Oncology 2012; 23(4): 942 doi: 10.1093/annonc/mdr317
|
| 12 |
Giuseppe Aprile, Claudio Avellini, Michele Reni, Micol Mazzer, Luisa Foltran, Diego Rossi, Stefano Cereda, Emiliana Iaiza, Gianpiero Fasola, Andrea Piga. Biglycan expression and clinical outcome in patients with pancreatic adenocarcinoma. Tumor Biology 2013; 34(1): 131 doi: 10.1007/s13277-012-0520-2
|
| 13 |
Alessandro Giardino, Roberto Girelli, Isabella Frigerio, Paolo Regi, Maurizio Cantore, Auriemma Alessandra, Annita Lusenti, Roberto Salvia, Claudio Bassi, Paolo Pederzoli. Triple approach strategy for patients with locally advanced pancreatic carcinoma. HPB 2013; 15(8): 623 doi: 10.1111/hpb.12027
|
| 14 |
Li Yu, Yunfei Liu, Zhiqiang Li, Yanyan Huang, Guangping Tu, Qiuling Shi, Lang Chen, Xiao Yu. A retrospective comparative study on the treatment of non-metastatic pancreatic cancer using high-intensity focused ultrasound versus radical surgery. International Journal of Hyperthermia 2024; 41(1) doi: 10.1080/02656736.2024.2398557
|
| 15 |
Robert A. Wolff. Chemotherapy for Pancreatic Cancer: From Metastatic Disease to Adjuvant Therapy. The Cancer Journal 2007; 13(3): 175 doi: 10.1097/PPO.0b013e318074e6c3
|
| 16 |
Justin M. Lebenthal, Junting Zheng, Paul A. Glare, Eileen M. O’Reilly, Andrew C. Yang, Andrew S. Epstein. Prognostic value of the Memorial Sloan Kettering Prognostic Score in metastatic pancreatic adenocarcinoma. Cancer 2021; 127(10): 1568 doi: 10.1002/cncr.33420
|
| 17 |
Dearbhaile Catherine Collins, Patrick Glyn Morris. Systemic therapy for advanced pancreatic cancer: individualising cytotoxic therapy. Expert Opinion on Pharmacotherapy 2015; 16(6): 851 doi: 10.1517/14656566.2015.1024654
|
| 18 |
Mohamedraed Elshami, Fasih A. Ahmed, Hanna Kakish, Jonathan J. Hue, Richard S. Hoehn, Luke D. Rothermel, David Bajor, Amr Mohamed, Jennifer E. Selfridge, John B. Ammori, Jeffrey M. Hardacre, Jordan M. Winter, Lee M. Ocuin. Average treatment effect of facility hepatopancreatobiliary cancer volume on survival of non-resected pancreatic adenocarcinoma. HPB 2022; 24(11): 1878 doi: 10.1016/j.hpb.2022.07.007
|
| 19 |
Shristi Upadhyay Banskota, Jonathan Q. Trinh, Elizabeth Lyden, Conor Houlihan, Samia Asif, Omar Abughanimeh, Benjamin A. Teply. Diagnosis of Metastatic Non-Small Cell Lung Cancer during Hospitalization: Missed Opportunity for Optimal Supportive Care?. Cancers 2024; 16(6): 1221 doi: 10.3390/cancers16061221
|
| 20 |
Pedro L. S. Usón Junior, Donato Callegaro-Filho, Diogo D. G. Bugano, Fernando Moura, Fernando C. Maluf. Predictive Value of Serum Carbohydrate Antigen 19-9 (CA19-9) for Early Mortality in Advanced Pancreatic Cancer. Journal of Gastrointestinal Cancer 2018; 49(4): 481 doi: 10.1007/s12029-017-0007-x
|
| 21 |
N. Haj Mohammad, N. Bernards, M. G. H. Besselink, O. R. Busch, J. W. Wilmink, G. J. M. Creemers, I. H. J. T. De Hingh, V. E. P. P. Lemmens, H. W. M. van Laarhoven. Volume matters in the systemic treatment of metastatic pancreatic cancer: a population-based study in the Netherlands. Journal of Cancer Research and Clinical Oncology 2016; 142(6): 1353 doi: 10.1007/s00432-016-2140-5
|
| 22 |
H.J. Stemmler, M. Schlemmer, S. Reilich. Rationale Bildgebung bei metastasierten Tumorerkrankungen. Der Internist 2013; 54(7): 803 doi: 10.1007/s00108-012-3241-0
|
| 23 |
Volker Heinemann, Stefan Boeck, Axel Hinke, Roberto Labianca, Christophe Louvet. Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer. BMC Cancer 2008; 8(1) doi: 10.1186/1471-2407-8-82
|
| 24 |
David Z. Chu. Improved Survival with Adjuvant External‐Beam Radiation Therapy in Lymph Node‐Negative Pancreatic Cancer. Cancer 2008; 113(5): 1110 doi: 10.1002/cncr.23602
|
| 25 |
Richard A. Burkhart, Yu Peng, Zoë A. Norris, Renée M. Tholey, Vanessa A. Talbott, Qin Liang, Yongxing Ai, Kathy Miller, Shruti Lal, Joseph A. Cozzitorto, Agnieska K. Witkiewicz, Charles J. Yeo, Matthew Gehrmann, Andrew Napper, Jordan M. Winter, Janet A. Sawicki, Zhihao Zhuang, Jonathan R. Brody. Mitoxantrone Targets Human Ubiquitin-Specific Peptidase 11 (USP11) and Is a Potent Inhibitor of Pancreatic Cancer Cell Survival. Molecular Cancer Research 2013; 11(8): 901 doi: 10.1158/1541-7786.MCR-12-0699
|
| 26 |
Stefan Boeck, Volker Heinemann. The Role of Second-Line Chemotherapy After Gemcitabine Failure In Patients With Advanced Pancreatic Cancer. Future Oncology 2008; 4(1): 41 doi: 10.2217/14796694.4.1.41
|
| 27 |
V. Heinemann. Future perspectives in the treatment of pancreatic cancer. memo - Magazine of European Medical Oncology 2008; 1(1): 27 doi: 10.1007/s12254-008-0007-4
|
| 28 |
Michael A van Geer, Conny T Bakker, Naoya Koizumi, Hiroyuki Mizuguchi, John G Wesseling, Ronald PJ Oude Elferink, Piter J Bosma. Ephrin A2 receptor targeting does not increase adenoviral pancreatic cancer transduction <italic>in vivo</italic>. World Journal of Gastroenterology 2009; 15(22): 2754-2762 doi: 10.3748/wjg.15.2754
|
| 29 |
Xin-yu Huang, Hong-cheng Wang, Zhou Yuan, Ang Li, Mei-lan He, Kai-xing Ai, Qi Zheng, Huan-long Qin. Gemcitabine combined with gum mastic causes potent growth inhibition and apoptosis of pancreatic cancer cells. Acta Pharmacologica Sinica 2010; 31(6): 741 doi: 10.1038/aps.2010.54
|
| 30 |
R Guilfoyle, A Demers, C Bredeson, E Richardson, M Rubinger, D Szwajcer, M D Seftel. Performance status, but not the Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI), predicts mortality at a Canadian transplant center. Bone Marrow Transplantation 2009; 43(2): 133 doi: 10.1038/bmt.2008.300
|
| 31 |
Don L. Gibbons, Robert A. Wolff, Gauri Varadhachary. Targeted Cancer Therapy. Current Clinical Oncology™ 2008; : 271 doi: 10.1007/978-1-60327-424-1_13
|
| 32 |
Thorvardur R Halfdanarson, Sigurdis Haraldsdottir, Mitesh J Borad. Advances in systemic therapy for advanced pancreatobiliary malignancies. F1000Research 2013; 2: 105 doi: 10.12688/f1000research.2-105.v1
|
| 33 |
Philip A. Philip, Lance K. Heilbrun, Judith Abrams. Pancreatic Cancer. 2008; : 723 doi: 10.1007/978-0-387-69252-4_44
|
| 34 |
Gaku Watanabe, Yukiyo Shimizu, Yuki Mataki, Kayo Tokeji, Yasushi Hada. A Multidisciplinary Rehabilitation Approach for a Patient With Diffuse Large B-cell Lymphoma and Bone Metastasis: A Case Report. Cureus 2024; doi: 10.7759/cureus.60713
|
| 35 |
S Boeck, A Jung, R P Laubender, J Neumann, R Egg, C Goritschan, U Vehling-Kaiser, C Winkelmann, L Fischer von Weikersthal, M R Clemens, T C Gauler, A Märten, S Klein, G Kojouharoff, M Barner, M Geissler, T F Greten, U Mansmann, T Kirchner, V Heinemann. EGFR pathway biomarkers in erlotinib-treated patients with advanced pancreatic cancer: translational results from the randomised, crossover phase 3 trial AIO-PK0104. British Journal of Cancer 2013; 108(2): 469 doi: 10.1038/bjc.2012.495
|
| 36 |
H. Oettle, M. Sinn. Hepatobiliäre und Pankreastumoren. 2010; : 380 doi: 10.1007/978-3-642-04935-4_39
|
| 37 |
Michael Haas, Ruediger P. Laubender, Christina Klose, Christoph Schulz, Ulrich Mansmann, Stefan Boeck, Volker Heinemann. External Validation of 2 Prognostic Indices for Patients With Advanced Pancreatic Cancer Treated With First-line Therapy. Pancreas 2012; 41(5): 738 doi: 10.1097/MPA.0b013e31823bcc7b
|
| 38 |
Sierra Cheng, Mahin Qureshi, Eleanor Pullenayegum, Adam Haynes, Kelvin K.W. Chan. Do patients with reduced or excellent performance status derive the same clinical benefit from novel systemic cancer therapies? A systematic review and meta-analysis. ESMO Open 2017; 2(4): e000225 doi: 10.1136/esmoopen-2017-000225
|
| 39 |
Kharat Aditi, Tan Chia Jie, Saeteaw Manit, Chhibber Anindit, Biskupiak Joseph, Veettil Sajesh K, Chaiyakunapruk Nathorn. Survival benefits and safety of chemotherapy regimens for pancreatic cancer: An umbrella review of meta-analyses of randomized controlled trials. Annals of Pancreatic Disorders and Treatment 2022; 4(1): 001 doi: 10.17352/apdt.000008
|
| 40 |
Annika Kurreck, Johanna Weckwerth, Dominik P. Modest, Jana K. Striefler, Marcus Bahra, Sven Bischoff, Uwe Pelzer, Helmut Oettle, Stephan Kruger, Hanno Riess, Marianne Sinn. Impact of completeness of adjuvant gemcitabine, relapse pattern, and subsequent therapy on outcome of patients with resected pancreatic ductal adenocarcinoma – A pooled analysis of CONKO-001, CONKO-005, and CONKO-006 trials. European Journal of Cancer 2021; 150: 250 doi: 10.1016/j.ejca.2021.03.036
|
| 41 |
Jonathan J. Hue, Kavin Sugumar, Amr Mohamed, J. Eva Selfridge, David Bajor, Jeffrey M. Hardacre, John B. Ammori, Luke D. Rothermel, Jordan M. Winter, Lee M. Ocuin. Assessing the Role of Operative Intervention in Elderly Patients With Nonfunctional Pancreatic Neuroendocrine Neoplasms. Pancreas 2022; 51(4): 380 doi: 10.1097/MPA.0000000000002023
|
| 42 |
Nicola Silvestris, Oronzo Brunetti, Enrico Vasile, Francesco Cellini, Ivana Cataldo, Valeria Pusceddu, Monica Cattaneo, Stefano Partelli, Mario Scartozzi, Giuseppe Aprile, Andrea Casadei Gardini, Alessio Giuseppe Morganti, Vincenzo Valentini, Aldo Scarpa, Massimo Falconi, Angela Calabrese, Vito Lorusso, Michele Reni, Stefano Cascinu. Multimodal treatment of resectable pancreatic ductal adenocarcinoma. Critical Reviews in Oncology/Hematology 2017; 111: 152 doi: 10.1016/j.critrevonc.2017.01.015
|
| 43 |
Mohit Butaney, Raj Satkunasivam, Hanan Goldberg, Stephen J. Freedland, Sandip P. Patel, Omid Hamid, Sumanta K. Pal, Zachary Klaassen, Christopher J.D. Wallis. Analysis of Heterogeneity in Survival Benefit of Immunotherapy in Oncology According to Patient Demographics and Performance Status. American Journal of Clinical Oncology 2020; 43(3): 193 doi: 10.1097/COC.0000000000000650
|
| 44 |
Jonathan I. Gotfried, Peter S. Kozuch. Case Report: Long-Term Survival in Patients with Initial Lung-Only Metastasis from Pancreatic Adenocarcinoma. Journal of Gastrointestinal Cancer 2012; 43(S1): 50 doi: 10.1007/s12029-011-9304-y
|
| 45 |
Yongsung Kim, Chandra Kumar Krishnan, Han-Soo Kim, Hwan Seong Cho, Ilkyu Han. Ambulation Recovery After Surgery for Metastases to the Femur. The Oncologist 2020; 25(1): e178 doi: 10.1634/theoncologist.2019-0107
|
| 46 |
|
| 47 |
An Ngo-Huang, Nathan H. Parker, Eduardo Bruera, Rebecca E. Lee, Richard Simpson, Daniel P. O’Connor, Maria Q. B. Petzel, Rhodora C. Fontillas, Keri Schadler, Lianchun Xiao, Xuemei Wang, David Fogelman, Sunil K. Sahai, Jeffrey E. Lee, Karen Basen-Engquist, Matthew H. G. Katz. Home-Based Exercise Prehabilitation During Preoperative Treatment for Pancreatic Cancer Is Associated With Improvement in Physical Function and Quality of Life. Integrative Cancer Therapies 2019; 18 doi: 10.1177/1534735419894061
|
| 48 |
Wei Fang Dai, Jaclyn Beca, Helen Guo, Wanrudee Isaranawatchai, Deborah Schwartz, Rohini Naipaul, Jessica Arias, Yao Qiao, Scott Gavura, Ruby Redmond‐Misner, Zahra Ismail, Lisa Barbera, Kelvin Chan. Are population‐based patient‐reported outcomes associated with overall survival in patients with advanced pancreatic cancer?. Cancer Medicine 2020; 9(1): 215 doi: 10.1002/cam4.2704
|
| 49 |
Nicolas Girard, Françoise Mornex, Nadine Bossard, Marc Ychou, Bruno Chauffert, Virginie Wautot. Estimating Optimal Dose of Twice-Weekly Gemcitabine for Concurrent Chemoradiotherapy in Unresectable Pancreatic Carcinoma: Mature Results of GEMRT-01 Phase I Trial. International Journal of Radiation Oncology*Biology*Physics 2010; 77(5): 1426 doi: 10.1016/j.ijrobp.2009.06.053
|
| 50 |
Andreas Hilbig, Helmut Oettle. Gemcitabine in the treatment of metastatic pancreatic cancer. Expert Review of Anticancer Therapy 2008; 8(4): 511 doi: 10.1586/14737140.8.4.511
|
| 51 |
Hedy Lee Kindler, Donna Niedzwiecki, Donna Hollis, Susan Sutherland, Deborah Schrag, Herbert Hurwitz, Federico Innocenti, Mary Frances Mulcahy, Eileen O'Reilly, Timothy F. Wozniak, Joel Picus, Pankaj Bhargava, Robert J. Mayer, Richard L. Schilsky, Richard M. Goldberg. Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303). Journal of Clinical Oncology 2010; 28(22): 3617 doi: 10.1200/JCO.2010.28.1386
|